This article is more than 5 years old. Information may no longer be current.

Lux Biosciences granted FDA fast track designation for corneal transplant rejection drug

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

JERSEY CITY, N.J. — The U.S. Food and Drug Administration has granted Lux Biosciences fast track designation for LX201, a silicone matrix ocular implant designed to steadily release therapeutic doses of cyclosporine A to prevent corneal transplant rejection, the company announced in a press release.

LX201 is currently being tested in a 1-year clinical trial program, which involves two controlled studies investigating LX201 in patients at increased immune-mediated risk of either rejection or graft loss after corneal transplantation.

The fast track drug development program is designed to promote the development of drugs to treat life-threatening or serious conditions, and requires that the drug demonstrate the potential to address unmet medical needs.